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The presence of a formyl blocking group at the N-terminus of the ATPase inhibitor has been identified 
and the partial sequence of the N-terminal peptide has been determined by fast atom bombardment and 
field desorption coupled to mass pectrometry. Minor discrepancies in amino acid sequence of the inhibitor 
between the present and published ata [(1981) Proc. Natl. Acad. Sci. USA 78, 7403-74071 are reported 
and its relationships with other inhbitors are briefly discussed. 
ATPase inhibitor N-formyl blocking group Fast atom bombardment 
Amino acid sequence 
Field desorption 
1. INTRODUCTION 
The natural mitochondrial ATPase inhibitor 
(IFi) is a small protein with it4, of -10000 which 
inhibits the ATPase activity by binding specifically 
to one of the 5 subunits forming the soluble part 
of the enzyme [ 1,2]. IF,, as well as other inhibitors 
of ATPases [3,4], have attracted considerable in- 
terest, and several studies have been carried out 
concerning their physiological role in the regula- 
tion of oxidative phosphorylation [1,5,6]. The 
amino acid sequence of the inhibitor from beef 
heart mitochondria has been determined [7], based 
predominantly on Edman degradation procedures. 
In studies aimed at establishing relationships bet- 
ween structure and biological activity of IFi 
[8-lo], we have been working on the determina- 
tion of the primary structure, and have employed 
several approaches including protease digestion, 
because the N-terminal residue was found to be 
undetectable by a variety of conventional methods, 
We report here the identification of formyl as N- 
terminal blocking group by direct M, and structure 
determination of the terminal tryptic nonapeptide, 
using FAB and FD mass spectrometry. Further 
structural modifications concerning the localiza- 
tion of amide groups, and an apparent in- 
homogeneity at the C-terminus were found by a 
complete reevaluation of the sequence. Possible 
reasons for the discrepancy with the previously 
reported, unblocked structure and relations of the 
beef heart inhibitor to similar inhibitors from 
other sources are briefly discussed. 
2. MATERIALS AND METHODS 
Abbreviations: IF,, natural ATPase inhibitor; HPLC, 
high-performance liquid chromatography; FAB, fast 
atom bombardment; FD, field desorption; Cpase, car- 
boxypeptidase; Apase, aminopeptidase 
Beef heart mitochondria were isolated as in [l I] 
and stored at - 2O’C. Purification of the inhibitor 
was performed; (i) following [ 121, as modified in 
[ 131, employing alcohol precipitation and subse- 
quent 3 min heating at 90°C; (ii) by replacing these 
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two steps with DEAE-cellulose (DE-52) 
chromatography in 10 mM Tris buffer (pH 8.0) 
and an NaCl gradient. With both procedures, 
SDS-polyacrylamide gel electrophoresis of pure in- 
hibitor [14] yielded a single band with an apparent 
M, of -10000. The ATPase inhibitory activity was 
assayed as in [ 11. 
N-terminal peptide fragments were obtained by 
limited digestion with trypsin and thrombin in 
50 mM NH&HsCOO/HCOs (pH 7.8) as in [9]. 
Fragments were separated either by gel elec- 
trophoresis followed by extraction [8], or reversed- 
phase HPLC [9]. Isolation of peptides for mass 
spectral analysis was performed with -30 nmol 
hydrolysate on a C-18 column (30 x 0.6 cm) with 
a 10 mM trifluoroacetic acid/acetonitrile gradient 
[9]. Mass spectra were obtained with a Finnigan 
MAT 3 12 double focusing spectrometer/SS-188 
data system. Details of instrumental equipment 
and experimental procedures for FAB and FD 
mass spectrometry have been described [15,16]. 
For the determination of FAB spectra, 1 yl peptide 
(-2 nmol) in 10% aqueous acetic acid mixed with 
1 ,ul glycerol as liquid matrix was loaded on the 
FAB target and bombarded with a 7 keV Xe” 
primary beam. FD mass spectra were obtained 
with high-temperature activated carbon emitters 
[15] loaded with - 1 nmol peptide in 10% acetic 
acid. FD mass spectral analysis of aliquots from 
carboxypeptidase (Cpase) digestion was performed 
with -1.5 nmol peptide, by accumulation of the 
complete desorption profile as in [ 171. FAB exact 
mass measurements were carried out at a resolu- 
tion of 6000 by peak matching [15] against the 
MH+ of Des-Arg’-bradykinin (m/z 905) as 
reference ion. 
Complete proteolysis of the inhibitor was per- 
formed by digestion (16 h, 37°C) with trypsin and 
L-r-chymotrypsin (Worthington) at pH 8.2, and 
with Staphylococcus aureus protease V8 (Miles) at 
pH 6.5, using 0.1 M pyridine-collidine-acetate 
buffers adjusted to the appropriate pH. Digestion 
mixtures were separated on an SP-Sephadex C25 
column (Pharmacia) with a gradient of increasing 
pH and ionic strength [ 181. Further purification 
was achieved by gel filtration on Biogel P-2, P-4, 
P-6 and P-10 columns (Biorad) with 70% formic 
acid or 1% NHdHCO3, depending on the size and 
solubility of the fragments. N-terminal sequence 
analysis was performed by manual 1191 and 
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automatic Edman degradation with a Beckman 
890 spinning cup sequenator. Phenylthiohydan- 
toins were identified by HPLC as in [20]. N- 
terminal sequences were further determined by 
digestion with Apase M and leucine Apase (Boehr- 
inger Mannheim) in 0.1 M pyridine-collidine- 
acetate (pH 8.2) at 37°C. C-terminal sequences 
were analyzed by Cpase digestion at 37°C followed 
by amino acid analysis [21], with the following en- 
zymes: Cpase A (Worthington) and B (Sigma) (pH 
8.5); Cpase P (Takara Shuzo, Tokyo) in 0.1 M 
pyridinium formate (pH 2.5). Hydrazinolysis 
followed by direct amino acid analysis was carried 
out as in [22]. 
3. RESULTS 
Automatic (100-200 nmol) as well as manual 
(30-50 nmol) Edman degradation of the inhibitor 
was repeatedly performed without success, 
yielding at most -3% glycine from protein isolated 
by either purification procedure. Further evidence 
for the blocked N-terminus was obtained from the 
following experiments which were all negative to 
reveal a detectable N-terminal residue: dansylation 
followed by TLC analysis; Apase M and leucine 
Apase digestion; dinitrophenylation and methyl- 
amine reaction [23]; incubation with pyroglu- 
tamate aminopeptidase (Boehringer Mannheim) 
and with acylamino acid-releasing enzyme [24] 
(donated by Dr S. Tsunasawa, Osaka University). 
Digestion of “C-succinylated inhibitor with 
trypsin yielded peptide fragments, separated by 
Biogel P-2 chromatography [ 181, one of which was 
shown to be the terminal peptide by amino acid 
composition (see below), but contained no 
radioactivity. No free amino terminus was also 
found for a tripeptide with the composition, 
SeriGluiGlyi, isolated after S. aureus V8 protease 
digestion. Limited digestion of the inhibitor with 
trypsin and thrombin both released a peptide iden- 
tified as T(l-9) [9], with the composition, 
Asp2SerzGly2GluiVallArgi, which was purified by 
HPLC and subjected to mass spectral analysis. 
While the C-terminus of this peptide was amenable 
to Cpase digestion, any conventional N-terminal 
method, i.e., Edman degradation, dansylation, 
dinitrophenylation and succinylation failed. Its 
FAB mass spectrum (fig.la) revealed an ion of 
highest mass at m/z 948 which was compatible 
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Fig.1. (a) FAB mass pectrum of the N-terminal peptide T(l-9) obtained by digestion of IFr with thrombin 191 and 
HPLC isolation; (b) FD mass pectrum of T(l-9) at 17-21 mA emitter heating current [17]; (c) FD mass pectrum of 
HCO-Met-Leu-Phe-Lys (&I = 565) at 16-19 mA emitter heating current. For other experimental conditions ee 
section 2. 
with the protonated molecular ion, MH+, of a for- 
mylated peptide by subtraction of the calculated 
Mr (919). The same, most abundant MH+ ion was 
obtained in the FD mass spectrum (fig. 1 b). Precise 
mass measurement of this ion yielded the elemental 
composition, C35H58N13018 (found: 948.4048; 
talc. 948.4027, S = 2.1 mu) which, due to the 
absence of other possible sites of formylation, 
established the identity of the amino-terminal for- 
my1 residue. The sequence of this peptide was, par- 
tially, deduced directly from the FAB spectrum, 
which by peptide bond cleavage yields 
characteristic fragment ions with protonat~ 
amino end groups [ 15,251. Thus, fragments at m/z 
920, 863, 776, 647, 503 and 389 led to the as- 
signment, HCO-Gly-Ser-Glu-(Ser,Gly)-Asp-Asn- 
153 
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Fig.2. Complete sequence of the ATPase inhibitor from beef heart mitochondria. Sequences in brackets ( I--l ) 
indicate peptides obtained by digestion with trypsin (T), trypsin digestion of “C-succinylated inhibitor (ST), digestion 
with cu-chymotrypsin (C) and S. aureus V8 protease (V). Arrows above peptide fragments (---‘ ) denote partial 
sequences obtained by manual Edman degradation, lower arrows (- ) denote partial sequences determined by car- 
boxypeptidase A, B and/or P digestion [&lo]. Fragments Tl, T2, Cl and C2 indicate tryptic/chymotryptic peptides 
obtained by limited proteolytic digestion. Positions lo-16 of Tl, and 34-52 of C2 were determined by automatic 
Edman degradation. Revised sequence positions [7] are indicated by boxes. 
(Val,Arg) (see scheme in fig.1). The sequence was 
complemented and confirmed by FD mass spectra 
after partial Cpase digestion [17], yielding MH+ 
ions at m/z 792, 693 and 578, and by digestion 
with S. aureus V8 protease. Notable was the ion of 
low abundance at m/z 920 due to the deformylated 
peptide in the FD spectrum (fig. lb), which was ob- 
tained at conditions that minimize fragmentation 
[15,17]. FD mass spectra of several N-formyl 
oligopeptides did not show any significant defor- 
mylated fragment ions, as illustrated by the spec- 
trum of HCO-Met-Leu-Phe-Lys (M = 565, fig. lc), 
which suggested the presence of a small amount of 
unblocked N-terminal tryptic peptide of IFr. 
The complete sequence of the inhibitor was 
determined by analysis of tryptic (T), chymotryptic 
(C) and S. aureus protease V8 (V) fragments 
(fig.2). Although the tryptic and chymotryptic 
peptides did not cover the entire protein, all pep- 
tides from the staphylococcal protease digestion 
were recovered and together provided sufficient 
overlapping for a conclusive sequence assignment. 
In addition to the N-terminal formyl group, 
modifications at 3 further sites (see boxes in fig.2) 
were obtained by this study, which otherwise is in 
accord with the previously published structure [7]. 
Positions 29/30 were assigned -Glnz9-Glu- instead 
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of -Glu29-Gln- [7] by sequence analysis of the frag- 
ment, T(26-32), which was confirmed by the S. 
aureus protease digest yielding only one peptide, 
V(27-3 1). Position 61 was shown to be Gln instead 
of Glu by the C-terminal sequences of fragments 
ST(38-62) and C(46-63), and by the staphylococ- 
cal digest which yielded only a single fragment, 
V(59-66) in that region. Thus, the sequences 
(58-62) and (65-69) are not repetitive as reported 
[7]. Furthermore, a detailed sequence analysis of 
the C-terminus revealed inhomogeneity by one Asp 
residue, since two peptides differing only by one 
terminal Asp were separated and identified both by 
tryptic [T(79-83), T(79-84)] and chymotryptic 
[C(78-83), C(78-84)] digestion. 
4. DISCUSSION 
The unequivocal identification of formyl as N- 
terminal blocking group of the beef heart 
mitochondrial ATPase inhibitor by low- and high- 
resolution FD and FAB mass spectrometry of its 
terminal tryptic peptide is consistent with the 
failure of all our previous conventional methods, 
but was surprising in view of the communication 
by authors in [7] who obtained the N-terminal se- 
quence without reporting a specific deblocking 
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Fig.3. Comparison of the amino acid sequence of natural ATPase inhibitors from (a) beef heart and (b) yeast S. 
cerevisiue mitochondria. (0) Common residues, (-) repeated sequence, (-) a-helix region, (*) P-turn, 
absence of P-sheet [29]. 
procedure. The possibility of artificial formyla- 
tion, upon treatment with formic acid, during 
isolation of the inhibitor and/or N-terminal pep- 
tides was, therefore, carefully examined and ap- 
pears to have been safely excluded: (i) by identical 
results (I 3% of terminal Gly by automatic Edman 
degradation) obtained with two different purifica- 
tion procedures of the inhibitor [7,13], one of 
which is especially mild and avoids heat treatment; 
(ii) peptides repurified in the presence of formic 
acid here and in [8,21] were successfully subjected 
to up to 40 steps of Edman degradation; (iii) 
purification of samples of the inhibitor and its ter- 
minal peptide used for mass spectral analysis was 
carried out without employing formic acid. 
Moreover, FD mass spectra of several model 
oligopeptides obtained from aqueous formic acid 
solutions did not show any ions due to formylation 
products. The presence of some de-formylated 
protein is suggested by the small amount of ter- 
minal Gly observed, and the minor ion at m/z 920 
due to the free peptide, T(l-9) (fig. lb). Besides 
possibly a different source of material, partial or 
complete deformylation of the inhibitor during 
purification procedures in [7] may then be a possi- 
ble reason for the discrepancy with the previous 
study. Only a few examples of natural N-formyl 
proteins or peptides, besides proteins with formyl- 
Met have been described [26,27]. As shown here, 
FD and FAB mass spectrometry using an ap- 
propriate terminal polypeptide fragment is par- 
ticularly suited for their direct structural 
identification. 
The biological significance of the formylated N- 
terminal part of IFi is uncertain, since the 
fragments Tl and T2 obtained by limited tryptic 
digestion (see fig.2) retained most of the ATPase 
inhibitory activity. In contrast, the smaller 
chymotryptic fragments Cl and C2 are devoid of 
activity. However, the biological activity was 
substantially reduced after Cpase P digestion of 
approx. 10 amino acids [lo]. With the use of these 
data, a structural comparison of the beef heart in- 
hibitor with the shorter sequence of 63 residues of 
the ATPase inhibitor from the yeast Sac- 
charomyces cerevisiae [3] revealed extensive 
homology with 26 common positions both at the 
central and the C-terminal region of the two pro- 
teins, suggesting the critical role of these areas for 
the biological function (fig.3). In comparison with 
the mammalian and yeast inhibitor, ATPase l - 
subunits from bacteria and chloroplasts [4,28] do 
not show any apparent structural similarity. 
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